Avidity Biosciences, Inc (RNAM)

Avidity Biosciences, Inc (RNAM) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Mar 3, 2026: market cap $11.2B.

Renalytix (RNAM) is a precision medicine diagnostics company specializing in AI-enabled in vitro solutions for chronic kidney disease (CKD). The company's primary revenue driver is its flagship product, KidneyIntelX.dkd, an FDA-approved and Medicare-reimbursed prognostic test designed to assess the risk of rapid kidney function decline in patients with type 2 diabetes and early-stage CKD.

RNAM financial model: income statement, cash flow and balance sheet